The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression

Conclusion: Taken together, our results demonstrated that cilostazol enhances LRP1 expression in liver by activating PPARγ through the PPRE in the LRP1 promoter. Increased hepatic LRP1 may be essential for the reduction of circulating triglycerides brought about by cilostazol.

Source: Metabolism - Clinical and Experimental - October 21, 2013 Category: Biomedical Science Authors: Hyung Jun Kim, Jae Hoon Moon, Hyun Min Kim, Mi Ra Yun, Byung Hun Jeon, ByungWan Lee, Eun Seok Kang, Hyun Chul Lee, Bong Soo Cha Tags: Basic Science Source Type: research